EUVIMEDEUVIMED entdecken
Open Access

Dopa Responsiveness in Parkinson's Disease

Sacha E Gandhi iD, Anahita Nodehi, Michael A Lawton, Katherine A Grosset, Vicky Marshall, Yoav Ben-Shlomo, Donald G Grosset

Movement Disorders Clinical Practice · 2024

DOI: 10.1002/mdc3.14139 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders Clinical Practice, 2024. Verfasst von Sacha E Gandhi und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Neuroscience and Psychology, University of Glasgow, Glasgow, United Kingdom. Hauptthemen laut MEDLINE: Parkinson Disease, Levodopa, Antiparkinson Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dopaminergic responsiveness is a defining feature of Parkinson's disease (PD). However, there is limited information on how this evolves over time.

Objectives

To examine serial dopaminergic responses, if there are distinct patterns, and which factors predict these.

Methods

We analyzed data from the Parkinson's Progression Markers Initiative on repeated dopaminergic challenge tests (≥24.5% defined as a definite response). Growth‐mixture modeling evaluated for different response patterns and multinomial logistic regression tested for predictors of these clusters.

Results

1525 dopaminergic challenge tests were performed in 336 patients. At enrolment, mean age was 61.2 years (SD 9.6), 66.4% were male and disease duration was 0.5 years (SD 0.5). 1 to 2 years after diagnosis, 48.0% of tests showed a definite response, but this proportion increased with longer disease duration (51.1–74.3%). We identified 3 response groups: “Striking” ( n = 29, 8.7%); “Excellent” ( n = 110; 32.7%) and “Modest” ( n = 197, 58.6%). Significant differences were as follows: striking responders commenced treatment earlier ( P = 0.02), were less likely to be on dopamine agonist monotherapy ( P = 0.01), and had better cognition ( P < 0.01) and activities of daily living ( P = 0.01). Excellent responders had higher challenge doses ( P = 0.03) and were more likely to be on combination therapy ( P < 0.01).

Conclusion

Three distinct patterns of the dopaminergic response were observed. As the proportion of PD cases with definite dopa responsiveness increased over time, the initial treatment response may be an unreliable diagnostic aid.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseLevodopaAntiparkinson AgentsHumansMaleFemaleMiddle AgedAgedDisease ProgressionDopamine AgentsTreatment Outcome

Stichwörter der Autor:innen

Parkinson's diseasedopa responselevodopa

Substanzen

LevodopaAntiparkinson AgentsDopamine Agents

Autor:innen und Institutionen

  • School of Neuroscience and Psychology, University of Glasgow, Glasgow, United Kingdom.
  • Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
  • Institute of Neurological Sciences, Glasgow, United Kingdom.

ORCID-Profile: Sacha E Gandhi

Zitieren

APA

Gandhi, S. E., Nodehi, A., Lawton, M. A., Grosset, K. A., Marshall, V., Ben-Shlomo, Y., & Grosset, D. G. (2024). Dopa Responsiveness in Parkinson's Disease. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.14139

Vancouver

Gandhi SE, Nodehi A, Lawton MA, Grosset KA, Marshall V, Ben-Shlomo Y, et al. Dopa Responsiveness in Parkinson's Disease. Movement Disorders Clinical Practice. 2024. doi:10.1002/mdc3.14139

BibTeX
@article{Gandhi2024,
  author = {Gandhi, Sacha E and Nodehi, Anahita and Lawton, Michael A and Grosset, Katherine A and Marshall, Vicky and Ben-Shlomo, Yoav and Grosset, Donald G},
  title = {Dopa Responsiveness in Parkinson's Disease},
  journal = {Movement Disorders Clinical Practice},
  year = {2024},
  doi = {10.1002/mdc3.14139}
}
Kostenlos starten →